Longitudinal study of immunity to SARS-CoV2 in ocrelizumab-treated MS patients up to 2 years after COVID-19 vaccination.
Kister I, Curtin R, Piquet AL, Borko T, Pei J, Banbury BL, Bacon TE, Kim A, Tuen M, Velmurugu Y, Nyovanie S, Selva S, Samanovic MI, Mulligan MJ, Patskovsky Y, Priest J, Cabatingan M, Winger RC, Krogsgaard M, Silverman GJ.
Kister I, et al. Among authors: pei j.
Ann Clin Transl Neurol. 2024 May 7. doi: 10.1002/acn3.52081. Online ahead of print.
Ann Clin Transl Neurol. 2024.
PMID: 38713096